Vyne Therapeutics Inc.
13F holders, Q4 2024 (December 31)At the end of Q4 2024, 34 institutions reported holding Vyne Therapeutics Inc. in their 13F filings, up 2 from Q3 2024. 8 opened new positions and 6 sold out. The largest holders were Cormorant Asset Management, LP ($4.7M), Eventide Asset Management, LLC ($4.4M) and Citadel Advisors ($4.1M). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Vyne Therapeutics Inc.
- CUSIP
- 92941V308
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $1.6M |
| Exits | 6 | $967K |
All 13F filers, Q3 2024 → Q4 2024: 602,105 shares bought and 646,991 shares sold, net −44,886 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 34 holders
| Cormorant Asset Management, LP | 0.26% | No change | 1,394,336 | $4.7M |
| Eventide Asset Management, LLC | 0.08% | No change | 1,394,336 | $4.4M |
| Citadel Advisors | 0.00% | Add +3.6% | 1,230,457 | $4.1M |
| Vanguard Group Inc. | 0.00% | Add +7.1% | 475,129 | $1.6M |
| Acorn Capital Advisors, LLC | 0.82% | — | 456,970 | $1.5M |
| Palo Alto Investors LP | 0.23% | No change | 445,434 | $1.5M |
| Exome Asset Management LLC | 0.89% | No change | 353,434 | $1.2M |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 0.02% | New | 245,800 | $823K |
| Schonfeld Strategic Advisors LLC | 0.00% | Add +4.8% | 176,658 | $592K |
| Adage Capital Partners Gp, L.L.C. | 0.00% | New | 154,134 | $516K |
| Parkman Healthcare Partners LLC | 0.07% | Reduce -24.6% | 152,973 | $512K |
| Geode Capital Management, LLC | 0.00% | Add +0.3% | 135,017 | $452K |
| BlackRock, Inc. | 0.00% | Add +0.3% | 83,314 | $279K |
| Susquehanna International Group, LLP | 0.00% | Add +17.4% | 70,832 | $237K |
| Prelude Capital Management, LLC | 0.02% | Reduce -8.8% | 59,400 | $199K |
| Bridgeway Capital Management, LLC | 0.00% | New | 36,958 | $124K |
| Royal Bank of Canada | 0.00% | Add +934.0% | 25,229 | $84K |
| Renaissance Technologies | 0.00% | Reduce -71.2% | 24,943 | $84K |
| Northern Trust Corp. | 0.00% | Reduce -35.7% | 23,971 | $80K |
| XTX Topco Ltd | 0.01% | New | 21,018 | $70K |
| Jane Street Group, LLC | 0.00% | New | 20,286 | $68K |
| Commonwealth Equity Services, LLC | 0.00% | No change | 18,298 | $61K |
| State Street Corp. | 0.00% | No change | 15,765 | $53K |
| Morgan Stanley | 0.00% | Add +139.0% | 4,299 | $14K |
| Bfsg, LLC | 0.00% | New | 3,500 | $12K |
| Bank of America Corp. | 0.00% | Reduce -34.5% | 1,491 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -37.3% | 1,386 | $5K |
| Mb, Levis & Associates, LLC | 0.00% | No change | 1,041 | $3K |
| UBS Group AG | 0.00% | Add +4407.1% | 631 | $2K |
| Cwm, LLC | 0.00% | New | 500 | $2K |
| JPMorgan Chase & Co. | 0.00% | Add +77.4% | 314 | $1K |
| Centerpoint Advisors, LLC | 0.00% | No change | 350 | $1K |
| Wells Fargo & Company | 0.00% | No change | 65 | $218 |
| FMR LLC | 0.00% | New | 5 | $17 |
"% of holder's portfolio" is VYNE THERAPEUTICS INC's weight in each manager's 13F, not the share of Vyne Therapeutics Inc. the manager owns.